255 related articles for article (PubMed ID: 26755491)
1. Retrospective evaluation of toceranib phosphate (Palladia) in cats with oral squamous cell carcinoma.
Wiles V; Hohenhaus A; Lamb K; Zaidi B; Camps-Palau M; Leibman N
J Feline Med Surg; 2017 Feb; 19(2):185-193. PubMed ID: 26755491
[TBL] [Abstract][Full Text] [Related]
2. Tolerability of toceranib phosphate (Palladia) when used in conjunction with other therapies in 35 cats with feline oral squamous cell carcinoma: 2009-2013.
Olmsted GA; Farrelly J; Post GS; Smith J
J Feline Med Surg; 2017 Jun; 19(6):568-575. PubMed ID: 26951557
[TBL] [Abstract][Full Text] [Related]
3. Toxicity and response in cats with neoplasia treated with toceranib phosphate.
Harper A; Blackwood L
J Feline Med Surg; 2017 Jun; 19(6):619-623. PubMed ID: 27090289
[TBL] [Abstract][Full Text] [Related]
4. Retrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia.
Berger EP; Johannes CM; Post GS; Rothchild G; Shiu KB; Wetzel S; Fox LE
J Feline Med Surg; 2018 Feb; 20(2):95-102. PubMed ID: 29172873
[TBL] [Abstract][Full Text] [Related]
5. Retrospective evaluation of toceranib phosphate (Palladia®) toxicity in cats.
Merrick CH; Pierro J; Schleis SE; Sones EA; Wright ZM; Regan RC; Siedlecki CT; Bergman PJ
Vet Comp Oncol; 2017 Sep; 15(3):710-717. PubMed ID: 27041701
[TBL] [Abstract][Full Text] [Related]
6. Retrospective evaluation of toceranib phosphate (Palladia) use in the treatment of feline pancreatic carcinoma.
Rosario CO; Musser ML; Yuan L; Mochel JP; Talbott J; Johannes CM; Berger EP
Can Vet J; 2023 Dec; 64(12):1143-1148. PubMed ID: 38046430
[TBL] [Abstract][Full Text] [Related]
7. Palliative radiation therapy outcomes for cats with oral squamous cell carcinoma (1999-2005).
Sabhlok A; Ayl R
Vet Radiol Ultrasound; 2014; 55(5):565-70. PubMed ID: 24766180
[TBL] [Abstract][Full Text] [Related]
8. Combining radiation therapy with zoledronate for the treatment of osteo-invasive feline oral squamous cell carcinoma.
Lundberg AP; Tran Hoang C; Billhymer A; Selting KA
Vet Comp Oncol; 2022 Dec; 20(4):788-796. PubMed ID: 35561080
[TBL] [Abstract][Full Text] [Related]
9. Survival of 54 cats with oral squamous cell carcinoma in United Kingdom general practice.
Hayes AM; Adams VJ; Scase TJ; Murphy S
J Small Anim Pract; 2007 Jul; 48(7):394-9. PubMed ID: 17559521
[TBL] [Abstract][Full Text] [Related]
10. A prospective, multi-centre, Veterinary Radiation Therapy Oncology Group study reveals potential efficacy of toceranib phosphate (Palladia) as a primary or adjuvant agent in the treatment of canine nasal carcinoma.
Ehling TJ; Klein MK; Smith L; Prescott D; Haney S; Looper J; LaDue T; Brawner W; Fidel J; Shiomitsu K; Green E; Saba C; Turek M; Farrelly J
Vet Comp Oncol; 2022 Mar; 20(1):293-303. PubMed ID: 34655275
[TBL] [Abstract][Full Text] [Related]
11. Retrospective evaluation of toceranib phosphate (Palladia) in the treatment of canine carcinomatosis and mesothelioma.
Hicks KA; Leeper HJ; Curran KM
Vet Comp Oncol; 2024 Jun; 22(2):245-254. PubMed ID: 38622074
[TBL] [Abstract][Full Text] [Related]
12. Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011-2018.
Lew FH; McQuown B; Borrego J; Cunningham S; Burgess KE
Vet Comp Oncol; 2019 Dec; 17(4):465-471. PubMed ID: 31069932
[TBL] [Abstract][Full Text] [Related]
13. Low dose meloxicam is safe and tolerable when combined with toceranib phosphate in cancer-bearing cats.
Keepman SJ; Pellin MA
J Feline Med Surg; 2022 Dec; 24(12):1187-1194. PubMed ID: 34923878
[TBL] [Abstract][Full Text] [Related]
14. Toxicity and outcome in cats with oral squamous cell carcinoma after accelerated hypofractionated radiotherapy and concurrent systemic treatment.
Marconato L; Weyland M; Tresch N; Rossi F; Leone V; Rohrer Bley C
Vet Comp Oncol; 2020 Sep; 18(3):362-369. PubMed ID: 31756259
[TBL] [Abstract][Full Text] [Related]
15. Treatment of oral squamous cell carcinoma with accelerated radiation therapy and concomitant carboplatin in cats.
Fidel J; Lyons J; Tripp C; Houston R; Wheeler B; Ruiz A
J Vet Intern Med; 2011; 25(3):504-10. PubMed ID: 21539605
[TBL] [Abstract][Full Text] [Related]
16. Use of cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II), a liposomal cisplatin analogue, in cats with oral squamous cell carcinoma.
Fox LE; Rosenthal RC; King RR; Levine PB; Vail DM; Helfand SC; MacEwen EG; Perez-Soler R; Calderwood-Mays M; Kurzman ID
Am J Vet Res; 2000 Jul; 61(7):791-5. PubMed ID: 10895902
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.
Bernabe LF; Portela R; Nguyen S; Kisseberth WC; Pennell M; Yancey MF; London CA
BMC Vet Res; 2013 Sep; 9():190. PubMed ID: 24079884
[TBL] [Abstract][Full Text] [Related]
18. Toceranib phosphate (Palladia) for the treatment of canine exocrine pancreatic adenocarcinoma.
Musser ML; Johannes CM
BMC Vet Res; 2021 Aug; 17(1):269. PubMed ID: 34380474
[TBL] [Abstract][Full Text] [Related]
19. Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study.
Chon E; McCartan L; Kubicek LN; Vail DM
Vet Comp Oncol; 2012 Sep; 10(3):184-93. PubMed ID: 22235941
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine as a radiosensitizer for nonresectable feline oral squamous cell carcinoma.
Jones PD; de Lorimier LP; Kitchell BE; Losonsky JM
J Am Anim Hosp Assoc; 2003; 39(5):463-7. PubMed ID: 14518654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
